Recent news highlights include Skinvisible filing a patent for an innovative obesity drug delivery system leveraging its Invisicare technology.

• Skinvisible filed a patent for an innovative obesity drug delivery system using its proprietary Invisicare polymer delivery technology, indicating ongoing R&D and expansion into obesity treatment markets [N1].

Skinvisible's proprietary Invisicare technology offers scientifically supported benefits that differentiate its topical delivery system in the skincare and pharmaceutical markets. The company's licensing model allows it to leverage established manufacturers' marketing and distribution capabilities, potentially enabling broad market reach without heavy capital investment. Progress in clinical trials by licensee Quoin Pharmaceuticals, including regulatory designations such as Orphan Drug and Fast Track, supports the potential for regulatory approvals and market entry for novel treatments like QRX003. The filing of patents for transdermal delivery of obesity and glucose-controlling agents indicates strategic expansion into large medical markets. These factors collectively provide a foundation for potential growth in licensing revenues and partnerships.

Skinvisible faces significant financial challenges, including limited revenue generation, net losses, and very low liquidity ratios, raising concerns about its ability to continue as a going concern without additional capital. The company's reliance on licensing agreements means revenue depends on the success and commercialization efforts of third parties, which may delay or limit income. Competition from larger, better-resourced companies may restrict market share and pricing power. Regulatory risks related to product claims and safety substantiation could result in costly reformulations or enforcement actions. Additionally, the company's stock is thinly traded on the OTCQB, leading to low liquidity and potential volatility, which may affect investor confidence and capital raising efforts.

Skinvisible's moat is primarily based on its patented polymer delivery system, Invisicare®, which offers unique advantages in topical drug delivery such as extended active ingredient retention, controlled release, reduced irritation, and moisture retention. The technology is protected by multiple patents and is licensed to pharmaceutical and consumer goods companies globally. The company's partnerships with licensees like Quoin Pharmaceuticals, which is advancing clinical trials for products using Invisicare, and Ovation Science, which holds exclusive rights for cannabinoid topical products, provide strategic avenues for commercialization. However, the moat is challenged by competitors with greater resources and longer market presence, and the company's reliance on licensing rather than direct product sales limits control over market penetration and revenue generation.

• Financial Condition and Liquidity: The company has insufficient cash and revenues to cover operational costs and faces doubt about continuing as a going concern. It requires additional capital to implement its business plan, with no assurance of successful financing.
• Dependence on Licensing Partners: Revenue depends on licensees such as Quoin Pharmaceuticals and Ovation Science to successfully develop, obtain regulatory approvals for, and commercialize products using Invisicare technology.
• Competitive Pressure: Competitors with longer histories, greater resources, and larger customer bases may outcompete Skinvisible, especially if the company cannot invest adequately in sales, marketing, and technology development.
• Regulatory Risks: FDA and FTC oversight of product claims and safety may lead to enforcement actions requiring reformulation, relabeling, or additional data, potentially impacting product commercialization.
• Stock Liquidity and Market Risks: The company's common stock trades on the OTCQB with low liquidity and trading volume, which may cause price volatility and difficulty for investors to sell shares.

• Skinvisible, Inc. is a pharmaceutical R&D company through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., focused on developing and patenting topical skin products using its proprietary polymer delivery system called Invisicare® [S1].
• The company targets the global skincare and dermatology market (~$80 billion) and the over-the-counter market (~$30 billion), as well as exploring other medical markets such as obesity [S1].
• Invisicare® is a patented polymer delivery system that enhances delivery of active ingredients in topical skin products, allowing extended duration on skin, controlled release, reduced irritation, and moisture retention while allowing skin to breathe [S1].
• Skinvisible's business model centers on out-licensing its patented prescription and OTC products featuring Invisicare® to established manufacturers and marketers globally, generating revenue from upfront fees and royalties [S1].
• Additional revenue streams include co-development services for pharmaceutical clients and life cycle management by reformulating products coming off patent with Invisicare technology [S1].
• The company has an exclusive license agreement with Quoin Pharmaceuticals for certain patents and products, including QRX003, a product using Invisicare technology targeting Netherton Syndrome, with clinical trials ongoing and regulatory designations such as Orphan Drug and Fast Track granted by FDA and EMA [S1].
• Quoin's clinical trials for QRX003 have shown positive initial data, clean safety profile, and protocol amendments aimed at enhancing data and expediting regulatory approval; trials include pediatric and international expansions [S1].
• Skinvisible also has a license agreement with Ovation Science for the manufacture and distribution of DermSafe hand sanitizer products and exclusive rights for Invisicare technology with cannabinoids for topical/transdermal products targeting obesity and metabolic health [S1].
• The company filed provisional patents in 2024 for transdermal delivery compositions for obesity drugs and glucose-controlling agents using Invisicare technology, aiming to improve drug efficacy and reduce side effects [S1].
• Financial snapshot as of 2026-06-30 shows quarterly revenue of $5,000 USD and a net loss of $255,533 USD; cash and equivalents were $66,037 USD as of 2021-12-31; current assets $33,301 USD and current liabilities $5,536,429 USD as of 2026-06-30, resulting in a current ratio of 0.01 and cash ratio of 0.01, indicating liquidity challenges [S2].
• The company acknowledges risks related to its financial condition, including doubts about continuing as a going concern due to insufficient cash and revenues, and the need to raise additional capital to implement its business plan [S1][S2].
• Skinvisible's common stock is quoted on the OTCQB market with low liquidity and trading volume, which may affect stock price volatility and investor ability to sell shares [S1].
• The company faces competition from firms with longer operating histories, greater resources, and larger customer bases; it must invest in sales, marketing, and technological development to remain competitive [S1].
• Regulatory risks include FDA and FTC oversight of product claims and safety substantiation, with potential enforcement actions that could require reformulation or relabeling of products [S1].
• Recent news includes Skinvisible filing a patent for an innovative obesity drug delivery system leveraging its Invisicare technology [N1].